Payment overview · 2025
General Payments
$553.91
29 reported records · 9 companies
Healthcare provider profile · identity verified
Anwar Ismail, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · KENNER, LA · NPI 1679501712
Verified facts
What the public records show
CMS Open Payments records show Anwar Ismail, M.D. received $553.91 in general payments during 2025 across 29 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 31.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ingrezza.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Eliquis by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Invega Sustenna by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Ingrezza by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $173.91 | 31.4% | 15 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $124.39 | 22.5% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $56.11 | 10.1% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $50.86 | 9.2% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $46.47 | 8.4% | 2 | 2025 |
| Luye Pharma (USA) Ltd. | Unresolved — no canonical attribution shown | $31.42 | 5.7% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $27.82 | 5.0% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.91 | 4.5% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $18.02 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $553.91 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $173.91 | 15 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $124.39 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $56.11 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $50.86 | 2 | 2025 |
Source payment records
|
|||||
| INVEGA Normalized: invega |
Drug | Janssen Pharmaceuticals, Inc | $46.47 | 2 | 2025 |
Source payment records
|
|||||
| ERZOFRI EXTENDED-RELEASE Normalized: erzofri extended release |
Drug | Luye Pharma (USA) Ltd. | $31.42 | 2 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Lundbeck LLC | $27.82 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $24.91 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 73 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
98 | 25 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
73 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Divalproex Sodium | Divalproex Sodium | 883 | 141 |
| Quetiapine Fumarate | Quetiapine Fumarate | 776 | 117 |
| Risperidone | Risperidone | 616 | 114 |
| Benztropine Mesylate | Benztropine Mesylate | 504 | 75 |
| Trazodone Hcl | Trazodone Hcl | 429 | 81 |
| Olanzapine | Olanzapine | 427 | 60 |
| Clozapine | Clozapine | 426 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 336 | 75 |
| Sertraline Hcl | Sertraline Hcl | 261 | 60 |
| Lorazepam | Lorazepam | 239 | 42 |
| Clonazepam | Clonazepam | 194 | 37 |
| Haloperidol | Haloperidol | 187 | 36 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 136 | 27 |
| Propranolol Hcl | Propranolol Hcl | 135 | 33 |
| Memantine Hcl | Memantine Hcl | 129 | 38 |
| Paroxetine Hcl | Paroxetine Hcl | 128 | 15 |
| Atorvastatin Calcium | Atorvastatin Calcium | 127 | 90 |
| Buspirone Hcl | Buspirone Hcl | 123 | 28 |
| Bupropion Hcl Sr | Bupropion Hcl | 122 | 21 |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 114 | 14 |
| Mirtazapine | Mirtazapine | 108 | 38 |
| Alprazolam | Alprazolam | 103 | 14 |
| Divalproex Sodium Er | Divalproex Sodium | 103 | 23 |
| Amlodipine Besylate | Amlodipine Besylate | 100 | 65 |
| Invega Sustenna | Paliperidone Palmitate | 98 | 25 |
| Lithium Carbonate | Lithium Carbonate | 94 | 17 |
| Aripiprazole | Aripiprazole | 81 | 22 |
| Ziprasidone Hcl | Ziprasidone Hcl | 81 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 80 | 24 |
| Oxcarbazepine | Oxcarbazepine | 79 | 18 |
| Lisinopril | Lisinopril | 77 | 62 |
| Ingrezza | Valbenazine Tosylate | 73 | suppressed |
| Gabapentin | Gabapentin | 72 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | suppressed |
| Diazepam | Diazepam | 67 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 18 |
| Amantadine | Amantadine Hcl | 63 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 58 | suppressed |
| Losartan Potassium | Losartan Potassium | 56 | 30 |
| Levothyroxine Sodium | Levothyroxine Sodium | 54 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 51 | 37 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 51 | 27 |
| Clonidine Hcl | Clonidine Hcl | 49 | 14 |
| Prazosin Hcl | Prazosin Hcl | 49 | 12 |
| Doxepin Hcl | Doxepin Hcl | 47 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 47 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 47 | suppressed |
| Carbamazepine | Carbamazepine | 45 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 42 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 41 | 14 |
| Metformin Hcl | Metformin Hcl | 36 | 22 |
| Levetiracetam | Levetiracetam | 34 | 14 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 30 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 26 | 16 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 25 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 24 | suppressed |
| Meloxicam | Meloxicam | 24 | 17 |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Potassium Chloride | Potassium Chloride | 23 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 22 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 22 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | 12 |
| Paliperidone Er | Paliperidone | 19 | suppressed |
| Trifluoperazine Hcl | Trifluoperazine Hcl | 19 | suppressed |
| Phenobarbital | Phenobarbital | 18 | suppressed |
| Carvedilol | Carvedilol | 16 | suppressed |
| Furosemide | Furosemide | 16 | 13 |
| Celecoxib | Celecoxib | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Eliquis | Apixaban | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $553.91 · 29 records | E.R. Squibb & Sons, L.L.C. | ABILIFY ASIMTUFII, AUSTEDO XR, CAPLYTA, COBENFY, ERZOFRI EXTENDED-RELEASE, FANAPT, INGREZZA, INVEGA, LYBALVI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ingrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error